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Myotonic dystrophy (DM) is an autosomal dominant
neuromuscular disorder associated with defects in many
tissues, including skeletal muscle myotonia, progressive
myopathy, and abnormalities in the heart, the brain, and
the endocrine system (Harper 1995). The clinical phe-
notype, which is notably variable, is subject to genetic
anticipation, the progressive worsening of symptoms,
and/or presentation of symptoms at an earlier age in
successive generations (Harper 1995). Both genetic an-
ticipation and variability of phenotype in patients with
DM were explained when an unstable CTG triplet–
repeat expansion was identified in the myotonin protein
kinase (DMPK) gene and shown to be responsible for
the disease (Aslanidis et al. 1992; Brook et al. 1992;
Buxton et al. 1992; Fu et al. 1992; Harley et al. 1992;
Mahadevan et al. 1992). Unaffected individuals usually
have 5–40 CTG repeats in the DMPK gene, but in an
affected population the number of repeats is dramati-
cally higher, sometimes even up to several hundred or
thousands of repeats. Six years after the discovery of
unstable CTG triplet–repeat expansion on chromosome
19q, significant amounts of experimental data have been
collected, but the molecular mechanisms involved in the
induction of the disease are still uncertain.
DM is unusual among triplet-repeat disorders in that
it is associated with a trinucleotide repeat occurring in
the 3′ UTR of a disease gene. On the basis of the dom-
inant transmission of DM, one would ordinarily expect
the disease allele mutation to affect protein structure,
but it is difficult to see how a CTG triplet repeat outside
the gene’s open reading frame (ORF) could affect the
DMPK protein. Thus, it has been hypothesized that CTG
expansion might affect DMPK expression at the tran-
scriptional or posttranscriptional level (Fu et al. 1993;
Krahe et al. 1995; Wang et al. 1995), and, indeed,
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DMPK protein levels are reduced in DM, with some
apparent differences between the adult and congenital
forms of the disease (Timchenko et al. 1995). However,
even if we assume that alleles with long CTG tracts are
null, haploinsufficiency does not seem to be an adequate
model for the transmission of DM. Analysis of Dmpk
knockout mice shows that even complete deletion of the
gene does not confer the DM phenotype (Jansen et al.
1996; Reddy et al. 1996). Rather, mice homozygous for
the Dmpk deletion show some abnormalities, such as
skeletal muscle weakness and myopathy, but do not have
the myotonia that is a hallmark of DM disease (Jansen
et al. 1996; Reddy et al. 1996). Thus, although DMPK
is clearly an important component of muscle, loss of its
expression cannot explain the complete DM phenotype.
These results prompted us to reevaluate our knowledge
of the basis for DM pathogenesis and to develop new
strategies for studies of molecular mechanisms of DM.
The overall correlation between CTG repeat length
and severity of the disease suggests that these repeats
represent the major cause of DM pathogenesis. Two new
hypotheses that proceed from this assumption are now
under intensive investigations. The first suggests that ex-
pansion of CTG repeats leads to the change in expression
of a neighboring gene, in particular, the myotonic dys-
trophy–associated homeodomain gene, which maps im-
mediately downstream of DMPK (Boucher et al. 1995;
Steinbach et al. 1998; Tapscott et al. 1998). The second
hypothesis, concerning the role of RNA CUG repeats in
DM pathogenesis, is the focus of this review.
RNA CUG Repeats in DM
The first experimental data suggesting a role for
DMPK mRNA containing CUG repeats in DM pathol-
ogy were obtained in the laboratory of Dr. E. P. Hoffman
(Wang et al. 1995). The authors showed that DMPK
polyA RNA is significantly reduced in muscle biopsy
samples from DM patients but that total RNA from
these same samples contains essentially normal levels of
DMPK transcripts (Krahe et al. 1995; Wang et al. 1995).
This effect of the repeat expansion on RNA processing
seems to act in trans on transcripts derived from the
wild-type allele of heterozygous DM individuals. Such
an explanation can account for the dominant transmis-
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sion of DM. By extension, we have proposed that CUG
repeat–containing DMPK RNA might also affect pro-
cessing of other mRNAs, perhaps by sequestering spe-
cific RNA-binding proteins. According to this model
(fig. 1), altered processing of different CUG-containing
mRNAs results in the tissue-specific features of DM.
In agreement with this hypothesis, several CUG-
binding proteins have been identified (Timchenko et
al. 1996b). The first of these proteins, now named
CUGBP1, has been shown to bind to CUG repeats, but
not to single-stranded DNA CTG repeats (Timchenko
et al. 1996a, 1996b). CUGBP1 is identical to a novel
human nuclear heterogeneous RNA-binding protein,
hNab50 (Timchenko et al. 1996a), which has been
found to interact with an RNA-binding protein from
yeast, which regulates RNA polyadenylation and trans-
port (Caskey et al. 1996; Timchenko et al. 1996a).
CUGBP1 belongs to a family of RNA-binding proteins
that contain three RNA-binding domains (Caskey et al.
1996; Timchenko et al. 1996a), and it is highly homol-
ogous to several other RNA-binding proteins expressed
in a variety of animal species. In flies, these binding
proteins localize to the nucleus, where they regulate
RNA splicing (Bell et al. 1991), but in vertebrates, they
may also act in the cytoplasm to regulate translation and
RNA stability (Levine et al. 1993; Myer et al. 1997).
CUGBP1, in particular, plays an important role in the
splicing of certain pre-mRNAs that contain CUG repeats
in their regulatory elements (Philips et al. 1998). Several
such repeats occur in regulatory elements that are needed
for the inclusion of an alternative exon 5 in cardiac
troponin T (cTnT). Philips et al. (1998) demonstrated
that CUGBP1 binds to CUG repeats in this pre-mRNA
and positively regulates inclusion of alternative exon
that is usually absent in the adult form of the protein.
Furthermore, splicing of cTnT RNA is indeed abnormal
in hearts of DM patients, with an increase of the inclu-
sion of alternative exon 5, as might be expected given
that CUGBP1 RNA-binding activity is increased in nu-
clei of DM patients (Timchenko et al. 1996a; Roberts
et al. 1997). These findings confirm the importance, for
regulation of muscle cell gene expression, of interactions
between CUG elements and specific RNA-binding pro-
teins. However, as discussed below, they are not com-
patible with a simple protein-sequestration model for
DM pathogenesis.
CUG-Binding Proteins in Translational Regulation
Since a significant amount of CUGBP1 is found in
cytoplasm, it has been suggested that this protein also
acts in postprocessing RNA regulation. Recently, we
found that CUGBP1 is associated with polyribosomes
and regulates translation of the transcription factor C/
EBPb (Timchenko et al. 1998). CUG-binding proteins
bind to CUG repeats located in the 5′ region of C/EBPb
mRNA and affect the use of three alternative ribosomal
initiation codons (Descombes and Schibler 1991), lead-
ing to the translation of different set of C/EBPb isoforms.
CUGBP1 also binds to the 3′ UTR of DMPK RNA
(Timchenko et al. 1996a) and may regulate its splicing
or translation. We suggest that CUGBP1, in addition to
other CUG-binding proteins, regulates a broad spectrum
of RNAs with CUG repeats. It is interesting to note that
Hoffman’s group found a reduction of insulin-receptor
mRNA and protein in muscle biopsy samples from pa-
tients with DM (Morrone et al. 1997). Although the
mechanism of reduction of insulin receptor is unknown,
it is possible that alteration of RNA processing in DM
cells affects expression of the insulin receptor consistent
with abnormal insulin resistance seen in patients with
DM (Harper 1995).
Recently, two other nuclear proteins with molecular
weights 25 and 35 kDa were isolated from human brain
by affinity purification with RNA (CUG)10 (Bhagwati
et al. 1996). Although the function of these proteins is
unknown, they might be affected by expansion of CUG
repeats in DM. We recently found that an elav-type
RNA-binding protein, ETR-3, also binds specifically to
expanded CUG repeats (Lu et al. 1999). This protein
exhibits 75% homology to CUGBP1 and has three
RNA-binding domains. Expression studies indicate that
ETR-3 is abundant in the human heart and therefore
could be involved in the regulation of RNA metabolism
of cardiac pre-mRNAs and mRNAs (Lu et al. 1999).
The identification of several proteins with CUG-binding
activity raises the question whether all or only a few of
the members of the CUG-binding protein family are af-
fected by CUG repeats. It is also important to know
whether CUG-binding proteins can be affected by any
CUG repeats or only by CUG repeats placed into a
DMPK environment.
CUGBP1 Function in DM
An outstanding question for the RNA-based model of
DM is how CUGBP1 expression and function are af-
fected by the DMPK mutation. Our original model held
that expanded CUG repeats in the mutant DMPK
mRNA sequester CUGBP1, causing reduced binding of
CUGBP1 to other RNAs (Caskey et al. 1996; Timchenko
et al. 1996a). However, analysis of CUGBP1 expression
in DM patients shows that the increase in CUG repeat
length correlates with a 3–4-fold induction of the
CUGBP1 protein (Timchenko et al. 1998). Similar ac-
tivation was found in tissues from transgenic mice ov-
erexpressing CUG repeats (author’s unpublished data).
The nature of this feedback mechanism is unknown, but
CUGBP1 phosphorylation may be involved (fig. 1) (Rob-
erts et al. 1997).
362 Am. J. Hum. Genet. 64:360–364, 1999
Figure 1 The role of RNA CUG repeats in DM pathogenesis.
Overexpression of CUG repeats leads to overproduction of RNA-bind-
ing sites for specific RNA-binding proteins. These proteins are se-
questered by expanded CUG repeats. Such sequestration results in the
altered expression of specific RNA CUG-binding proteins. One such
protein, CUGBP1, is induced, leading to altered splicing and trans-
lation of CUG-containing mRNAs and causing abnormalities in a va-
riety of tissues, including the brain, heart, testes, and skeletal muscle.
Another important question concerns the tissue-
specific regulation of CUGBP1 target mRNAs. DM is
primarily a muscular disorder characterized by marked
atrophy in the adult form of the disease and by the
presence of immature myofibers in the congenital con-
dition (Harper 1995). It is likely that long CUG repeats
in the 3′ UTR of DMPK affect the maintenance of muscle
differentiation status via CUGBP1 or other related pro-
teins. A similar situation has been described for the 3′
UTRs of muscle-specific genes, such as troponin I, tro-
pomyosin, and a-cardiac actin (Rastinejad and Blau
1993). It has been demonstrated that the 3′ UTRs of
each of these mRNAs can rescue the mutant phenotype
of differentiation-defective myoblast mutant cell lines,
permitting these cells to reach their differentiated state
in culture. The mechanism of this effect on muscle-cell
phenotype remains uncertain, but because there is no
common ORF in these various 3′ UTRs, it is unlikely
that the mechanism requires the synthesis of any peptides
that might be encoded in these sequences. Rastinejad
and Blau (1993) suggest several models by which an
untranslated RNA could affect cell physiology, such as
by sequestering, by activating specific proteins or other
RNA species, or by acting as a ribozyme.
We suggest that a CUG repeat in the 3′ UTR of DMPK
also can play such a role. Sabourin et al. (1997) dem-
onstrated that the 3′ UTR of DMPK mRNA is important
for muscle differentiation. In contrast to the 3′ UTRs of
troponin I, tropomyosin, and a-cardiac actin, the 3′ UTR
of DMPK represses differentiation of mouse C2C12
cells, possibly by inhibiting myogenin expression. The
3′ UTR sequences important for the delay in muscle mat-
uration do not include CTG repeats, but the authors
speculate that CUG repeat expansion alters the structure
of DMPK mRNA and that this alteration affects binding
of RNA-binding proteins to the regions outside CUG
repeats. If so, expanded CUG repeats might affect not
only CUG-binding proteins, but also other RNA-binding
proteins that interact with other elements of the DMPK
3′ UTR.
Further investigations are necessary to identify and
characterize these proteins, but if this model is correct,
proteins that bind the 3′ UTR of DMPK RNA will
emerge as strong candidates for regulators of DM path-
ogenesis. Furthermore, changes in DMPK protein are
known to alter the expression of skeletal muscle–specific
genes, such as myogenin and the differentiation-depen-
dent isoform of b-tropomyosin, which are induced by
DMPK, and vimentin and retinoblastoma (Rb), which
are repressed (Bush et al. 1996). This pattern of gene
expression agrees with the positive role of DMPK in
muscle differentiation. Myopathy in homozygous
DMPK-knockout mice also shows that DMPK is im-
portant for muscle function (Reddy et al. 1996).
Our data thus suggest a complex relationship between
DMPK and CUGBP1. CUGBP1 regulates DMPK RNA
processing (X. Lu, L. Timchenko, unpublished data), so
abnormalities in CUGBP1 should affect DMPK expres-
sion. DMPK, in turn, affects the expression of muscle-
specific genes dependent on DMPK, some of which ap-
pear to be required to establish or maintain normal mus-
cle cell differentiation. In addition, it has been suggested
that CUGBP1 could be regulated by DMPK via phos-
phorylation (Roberts et al. 1997). Hence, both proteins
might contribute to the muscle function. The evidence
that CUGBP1 regulates patterns of C/EBPb synthesis
suggests that other transcription factors implicated in
the muscle differentiation may also be affected. Thus,
alteration of CUGBP1 expression in patients with DM
could affect transcription, translation, and processing of
muscle RNAs (fig. 1). Similar abnormalities of RNA me-
tabolism could occur in other affected tissues, including
the heart, brain, and testes. Identification of tissue-spe-
cific RNA-binding proteins interacting with the 3′ UTR
of DMPK and CUG repeats will be required for the
understanding of the role of RNA mechanism in man-
ifestation of disease.
Future Prospects
It is clear that the molecular basis for DM is complex
and consists of several steps. If, as I have argued, RNA
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CUG repeats are the major factor in DM pathogenesis,
several important issues must still be resolved. First,
other CUG repeat–binding proteins should be identified.
Second, various tissue-specific responses to CUG repeats
expansion should be analyzed. Third, the functions of
different CUG-binding proteins and the effect of over-
expression of CUG repeats on their activities should
be examined. Finally, that some cases of DM may be
associated not with DMPK but with the mutation or
deletion of some CUG-binding proteins, or with the
expansion of CUG repeats in other RNAs, should be
anticipated.
Regarding the last point, a new locus for DM (DM2),
which was recently mapped to 3q (Ranum et al. 1998),
appears to cause classical features of DM, including
myotonia, myopathy, cataracts, and cardiac abnormal-
ities. Clinical evaluation of a five-generation family
shows that the phenotype is consistent with anticipation.
I suggest that DM2 could be associated with CTG re-
peats in a gene different from DMPK or with another
type of triplet-repeat expansion. Our data also suggest
that an RNA-based mechanism of pathogenesis may also
contribute to other neurologic disorders. For example,
a molecular analysis of a new type of spinocerebellar
ataxia (SCA 8) showed that the disease might be asso-
ciated with long CTG expansions in the 3′ UTR of a
novel gene with unknown function (Koob et al. 1998).
It will be interesting to examine whether CUG-binding
proteins are affected in this disease. If so, it is possible
that common, RNA-based pathways lead to each of
these disorders.
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